Full text is available at the source.
Abstract
Finerenone, SGLT2 inhibitors, and semaglutide are being compared for their effects on kidney health in diabetes.
- The study aims to evaluate the effectiveness of finerenone in treating diabetic kidney disease.
- SGLT2 inhibitors may have a role in improving kidney function in patients with diabetes.
- Semaglutide is being assessed for its potential benefits in kidney health alongside other treatments.
- The combination therapy of finerenone and SGLT2 inhibitors could provide additional therapeutic options.
Simplified